Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2780-2784

  Jayol, Aurélie ^a   Nordmann, Patrice ^a,b   Brink, Adrian ^c   Poirel, Laurent ^a  

^a University of Fribourg   (Switzerland)

^b Hopital Cantonal de Fribourg   (Switzerland)

^c MILPARK HOSPITAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; PHOP PROTEIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE DISRUPTION; KLEBSIELLA PNEUMONIAE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; WILD TYPE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLISTIN; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS;

EID: 84931274838     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05055-14     Document Type: Article

References (27)

1. Podschun R, Ullmann U. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11:589-603.
2. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654-663. http://dx.doi.org/10.1128/AAC.01222-13.
3. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422. http://dx.doi.org/10.1016/S0140-6736(97)80051-7.
4. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 66:946-947. http://dx.doi.org/10.1093/jac/dkr007.
5. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62: 1311-1318. http://dx.doi.org/10.1093/jac/dkn425.
6. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
7. Falagas ME, Rafailidis PI, Matthaiou DK. 2010. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updat 13:132-138. http://dx.doi.org/10.1016/j.drup.2010.05.002.
8. Humphries RM. 2015. Susceptibility testing of the polymyxins: where are we now? Pharmacotherapy 35:22-27. http://dx.doi.org/10.1002/phar.1505.
9. Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P, D'Andrea MM, Rossolini GM. 2014. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment. Antimicrob Agents Chemother 58:4399-4403. http://dx.doi.org/10.1128/AAC.02555-14.
10. Cheng HY, Chen YF, Peng HL. 2010. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J Biomed Sci 17:60. http://dx.doi.org/10.1186/1423-0127-17-60.
11. Choi MJ, Ko KS. 2014. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother 69:275-277. http://dx.doi.org/10.1093/jac/dkt315.
12. Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P. 2014. Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin. Antimicrob Agents Chemother 58:4762-4766. http://dx.doi.org/10.1128/AAC.00084-14.
13. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, Gaibani P, Rossolini GM. 2013. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemase mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 57:5521-5526. http://dx.doi.org/10.1128/AAC.01480-13.
14. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K, Vatopoulos A, Rossolini GM. 2014. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother 58: 5696-5703. http://dx.doi.org/10.1128/AAC.03110-14.
15. Poirel L, Jayol A, Bontron S, Villegas MV, Özdamar M, Turkoglü S, Nordmann P. 2015. The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother 70:75-80. http://dx.doi.org/10.1093/jac/dku323.
16. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD. 2015. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother 59:536-543. http://dx.doi.org/10.1128/AAC.04037-14.
17. Gunn JS. 2008. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol 16:284-290. http://dx.doi.org/10.1016/j.tim.2008.03.007.
18. Groisman EA. 2001. The pleiotropic two-component regulatory system PhoP-PhoQ. J Bacteriol 183:1835-1842. http://dx.doi.org/10.1128/JB.183.6.1835-1842.2001.
19. Mitrophanov AY, Jewett MW, Hadley TJ, Groisman EA. 2008. Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. PLoS Genet 4:e1000233. http://dx.doi.org/10.1371/journal.pgen.1000233.
20. Potron A, Poirel L, Rondinaud E, Nordmann P. 2013. Intercontinental spread of OXA-48 β-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 18(31):pii=20549. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20549.
21. th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 51:1678-1684. http://dx.doi.org/10.1128/JCM.03385-12.
23. Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2012. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis 74:412-414. http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.025.
24. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0. http://www.eucast.org/clinical-breakpoints/.
25. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
26. Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. 2005. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 43:4178-4182. http://dx.doi.org/10.1128/JCM.43.8.4178-4182.2005.
27. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53:3628-3634. http://dx.doi.org/10.1128/AAC.00284-09.